Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies

@article{Tomic2018NonalcoholicFL,
  title={Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies},
  author={Dunya Tomic and William Kemp and Stuart K. Roberts},
  journal={European Journal of Gastroenterology \& Hepatology},
  year={2018},
  volume={30},
  pages={1103–1115}
}
Nonalcoholic fatty liver disease (NAFLD) is now the most prevalent liver disease in the world. It involves a spectrum of conditions from hepatic steatosis to nonalcoholic steatohepatitis and liver fibrosis, and is a major cause of cirrhosis and hepatocellular carcinoma. It is defined by presence of steatosis in 5% of hepatocytes or more in the absence of other causes of fatty liver. The metabolic syndrome is the major known risk factor for NAFLD. Dietary contributors such as high fructose… 

Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective.

Non-alcoholic fatty liver disease and lipotoxicity

An overview of the main lipids involved in the pathogenesis of non-alcoholic fatty liver disease is presented and their association with lipotoxicity, insulin resistance, oxidative stress and other processes responsible for its progression are summarized.

Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation.

  • B. Maliakkal
  • Medicine, Biology
    Translational gastroenterology and hepatology
  • 2020
While CVD is the most common cause of non-graft related mortality over the long-term, the short and intermediate-term survival post LT in NAFLD cirrhosis appears to be on par with other etiologies when age and comorbidities are factored.

Non-alcoholic fatty liver disease—A pilot study investigating early inflammatory and fibrotic biomarkers of NAFLD with alcoholic liver disease

Single biomarkers are unlikely to be diagnostic or predictive at staging NAFLD due to the complex heterogeneity of the disease, however, biomarker combinations may help stratify risk and stage disease where patients are averse to biopsy.

Benefits of the Therapy With Abexol in Patients With Non-Alcoholic Fatty Liver Disease

Treatment of Abexol during 6 months significantly ameliorates liver fat accumulation and insulin resistances, meanwhile improving clinical evolution in patients with NAFLD.

SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions

This narrative review summarizes the current understanding of the diagnosis, epidemiology, and pathophysiology of NAFLD and specifically focuses on the efficacy of SGLT2i(s) as a potentially promising group of agents for the management of patients with NA FLD.

Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus

This review aims to shed some light on the intricate relationship between NAFLD and T2DM and how IR links both diseases and to raise awareness among clinicians about this relationship and how the presence of one disease should raise a high index of suspicion for the existence of the other.

Waist-to-height ratio and non-alcoholic fatty liver disease in adults

The results suggest that in adults, the WHtR is associated with NAFLD, and the association is not purely linear but non-linear, with significant threshold and saturation effects.

Study on the correlation between urinary retinol-binding protein and nonalcoholic fatty liver disease

The results revealed that the urinary RBP/creatinine ratio was an independent risk factor for NAFLD.

Association of epicardial adipose tissue with non-alcoholic fatty liver disease: a meta-analysis

The increase in the EAT was associated with the severity of steatosis, fibrosis and cardiovascular disease in patients with NAFLD and provide new information regarding the development and progression ofNAFLD.

References

SHOWING 1-10 OF 169 REFERENCES

The Metabolic Syndrome as a Predictor of Nonalcoholic Fatty Liver Disease

Evaluated the cross-sectional relationship between the metabolic syndrome, defined by the modified ATP III criteria, and the prevalence of nonalcoholic fatty liver disease in Japanese persons and addressed longitudinal aspects of the disease and its development and regression.

Diagnosis and therapy of nonalcoholic steatohepatitis.

Most therapeutic modalities available or under development target the major pathways thought essential in the pathogenesis of nonalcoholic steatohepatitis and often are directed at reducing body mass index and improving insulin resistance via pharmacologic, surgical, dietary, or exercise regimens.

Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy

Data indicate that obesity plays a greater role than excessive alcohol intake in inducing fatty liver, and the relative roles of obesity and alcohol abuse, alone and in combination, in inducing steatosis are explored.

Nonalcoholic steatohepatitis and increased risk of chronic kidney disease.

Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease

There is a significant prevalence of NAFL and potentially significant liver disease, including cryptogenic cirrhosis, in this predominantly nonobese, nonaffluent population in a developing country and NAFL will be a major determinant of future liver disease burden in countries of the developing world.

Nonalcoholic steatohepatitis.

  • A. Reid
  • Medicine
    Gastroenterology
  • 2001
Treatment of NASH is unproven, but weight reduction is recommended in obese patients, and Orthotopic liver transplantation is the treatment of choice for end-stage liver disease secondary to NASH.

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

The entire histologic spectrum of NAFLD can be seen in individuals with normal ALT values, and the Histologic spectrum in these individuals is not significantly different from those with elevated ALT levels, which means a lownormal ALT value does not guarantee freedom from underlying steatohepatitis with advanced fibrosis.
...